Skip to main content
    Z

    Zenas BioPharma, Inc. Common Stock (ZBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.93
    -0.08 (-0.29%)

    Market Cap: $1.90B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zenas BioPharma, Inc. Common Stock (ZBIO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Zenas BioPharma, Inc. Common Stock are Xencor (XNCR), Vir Biotechnology (VIR) and Harmony Biosciences Holdings (HRMY). By market cap, Zenas BioPharma, Inc. Common Stock ranks 9th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B.

    Peer Comparison

    ZBIO's ROIC of -104.3% is below the peer median of -18.7%, and its revenue growth of -100.0% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Harmony Biosciences Holdings (HRMY)$1.98B9.6x1.9x18.0%13.7%12.3%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Biohaven Ltd. (BHVN)$2.09BN/AN/A0.0%-315.9%0.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Xenon Pharmaceuticals Inc (XENE)$3.98BN/AN/A0.0%N/A-100.0%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Vor Biopharma Inc (VOR)$1.19BN/AN/A0.0%N/A0.0%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Sellas Life Sciences Group Inc (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Peer median$2.06B138.0x6.7x-0.0%-18.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Zenas BioPharma, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Harmony Biosciences Holdings (HRMY)
    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders.
    HRMY competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Biohaven Ltd. (BHVN)
    Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders...
    BHVN competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Xenon Pharmaceuticals Inc (XENE)
    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders...
    XENE competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Vor Biopharma Inc (VOR)
    Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients.
    VOR competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Sellas Life Sciences Group Inc (SLS)
    SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications...
    SLS competitors

    Frequently Asked Questions About ZBIO

    Who are Zenas BioPharma, Inc. Common Stock's main competitors?

    The companies most similar to Zenas BioPharma, Inc. Common Stock include Xencor (XNCR), Vir Biotechnology (VIR), Harmony Biosciences Holdings (HRMY), Nuvation Bio (NUVB) and Beam Therapeutics (BEAM), listed from the closest match.

    Who is Zenas BioPharma, Inc. Common Stock's biggest competitor?

    Xenon Pharmaceuticals (XENE) is the largest of the similar companies at $3.98B; Xencor (XNCR) is the closest match by business profile, size, sector and industry.

    How does ZBIO stock compare with its competitors?

    ZBIO's P/S is 168.0x against a peer median of 6.7x; its net margin is 0.0% against a peer median of -0.0%.

    Which of Zenas BioPharma, Inc. Common Stock's competitors pays a higher dividend?

    Zenas BioPharma, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Zenas BioPharma, Inc. Common Stock bigger than its competitors?

    No. Zenas BioPharma, Inc. Common Stock is 9th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.